{"id":251701,"date":"2024-04-02T02:47:42","date_gmt":"2024-04-02T02:47:42","guid":{"rendered":"https:\/\/namso-gen.co\/blog\/?p=251701"},"modified":"2024-04-02T02:47:42","modified_gmt":"2024-04-02T02:47:42","slug":"how-did-gilead-value-kite-at-11-9-billion","status":"publish","type":"post","link":"https:\/\/namso-gen.co\/blog\/how-did-gilead-value-kite-at-11-9-billion\/","title":{"rendered":"How did Gilead value Kite at 11.9 billion?"},"content":{"rendered":"

**How did Gilead value Kite at 11.9 billion?**<\/p>\n

In 2017, Gilead Sciences Inc., a renowned biopharmaceutical company, made headlines with its $11.9 billion acquisition of Kite Pharma, a pioneering developer of cutting-edge cancer treatments. This significant deal undoubtedly raised eyebrows and left many wondering how Gilead arrived at this seemingly hefty valuation. Let us delve deeper into the factors that contributed to Gilead’s assessment of Kite Pharma’s value.<\/p>\n

The primary factor that influenced Gilead’s valuation of Kite Pharma was the immense potential of its revolutionary CAR-T therapy. Chimeric Antigen Receptor T-cell therapy, commonly known as CAR-T, involves reprogramming a patient’s immune cells to enhance their ability to target and destroy cancer cells. Kite Pharma was at the forefront of developing this groundbreaking treatment and had achieved unprecedented success in clinical trials. With promising results and a strong pipeline, Gilead saw the immense potential for CAR-T therapy to revolutionize cancer treatment, leading them to place a high value on Kite.<\/p>\n

Furthermore, Kite Pharma possessed a robust intellectual property portfolio, providing another significant rationale for Gilead’s valuation. Patents and proprietary technologies are highly valuable in the pharmaceutical industry, as they grant exclusivity and market control. Kite Pharma’s strong IP position, including patent protection for its CAR-T therapy and associated manufacturing processes, made it a highly desirable acquisition target for Gilead. The value of this intellectual property significantly contributed to Gilead’s assessment of Kite Pharma’s worth.<\/p>\n

Additionally, Kite Pharma had successfully received approval from the U.S. Food and Drug Administration for its first CAR-T therapy, Yescarta, to treat certain types of aggressive non-Hodgkin lymphoma. This regulatory approval played a crucial role in Gilead’s valuation since it indicated the therapy’s market potential and future revenue streams. Gilead recognized the commercial viability of Kite Pharma’s CAR-T therapy and factored in its market success to justify the $11.9 billion valuation.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n